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Emerging evidence suggests intestinal microbiota as a central contributing factor
to the pathogenesis of Relapsing-Remitting-Multiple-Sclerosis (RRMS). This novel
RRMS study evaluated the impact of fecal-microbiota-transplantation (FMT) on a
broad array of physiological/clinical outcomes using deep metagenome sequencing
of fecal microbiome. FMT interventions were associated with increased abundances
of putative beneficial stool bacteria and short-chain-fatty-acid metabolites, which were
associated with increased/improved serum brain-derived-neurotrophic-factor levels and
gait/walking metrics. This proof-of-concept single-subject longitudinal study provides
evidence of potential importance of intestinal microbiota in the pathogenesis of MS, and
scientific rationale to help design future randomized controlled trials assessing FMT in
RRMS patients.
Keywords:multiple sclerosis, relapsing-remittingmultiple sclerosis, fecalmicrobiota transplantation,microbiome,
metabolomics, short-chain fatty acids, brain-derived neurotrophic factor, gait
INTRODUCTION
Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the Central
Nervous System (CNS) (1, 2). The pathological characteristics of MS is associated with the
formation of demyelinating lesions primarily affecting the CNS white matter (1, 2). Focal
lymphocytic infiltration is thought to be caused by the host’s immune cells, including activated
T cells and a significant contribution from B cells, accompanied by an abnormal blood brain
barrier, which leads to the inflammatory/damaging lesions and plaques on the myelin and axons
of the CNS (1, 2). Over time, damaged myelin causes impaired nerve signaling (axonal damage),
leading to neurodegeneration and associated motor function degradation. MS is predominately
in young adults (20–45 years of age) and affects twice as many women as men (3). Common
symptoms include numbness, fatigue/weakness, visual impairment, gait, constipation, urinary
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bladder dysfunction, and depression (3). A brain MRI scan is
the most useful test for confirming the diagnosis of MS (4).
Currently, more than 2 million patients worldwide suffer from
MS (5).
There are four clinical MS forms: relapsing-remitting-MS
(RRMS), secondary-progressive-MS, primary-progressive-MS,
and progressive-relapsing-MS (1, 2). Most common phenotype
of MS (80% of cases) is RRMS, characterized by alternating
periods of acute inflammation (relapses) and periods of
relative clinical stability devoid of new neurological symptoms
(remissions) (6). Inflammatory demyelinating focal white matter
lesions dominate the pathology in acute MS and RRMS (1). As
of 2020, the Federal Drug Administration (FDA) has approved
multiple medications to suppress this immune/inflammatory
cascade to prevent relapses, accumulation of lesions on magnetic
resonance imaging (MRI), and disability progression. Yet,
none of the medications have been shown to provide a cure
for MS. With the cause of the disease still unknown, better
understanding of the trigger for this immuno-inflammatory
cascade is essential for developing more effective and
novel therapeutic target(s) to inhibit progression of this
debilitating disease.
Intestinal microbiome has been identified as a potential
trigger modulating the host’s immune and nervous system
function in MS (7). Preclinical animal models of MS and cross-
sectional observational studies in MS patients have reported
altered intestinal (stool) microbiota communities (“dysbiosis”)
which were associated with systemic inflammatory autoimmune
responses of the host (8–11). Majority of MS intestinal dysbiotic
microbiota data is characterized by decreases in the relative
abundance of short-chain-fatty-acids (SCFA)-producing bacteria
(e.g., Faecalibacterium prausnitzii) (11, 12). Elsewhere, prior
studies demonstrated that low levels of SCFAs are associated
with disruption of intestinal barrier and endotoxin leak (13–16).
SCFAs, especially butyrate, enhance barrier function, and anti-
inflammatory activities (17–19). Thus, a low SCFA-producing
microbial community could mediate an inflammatory trigger
in MS.
Accordingly, microbiota-directed interventions, like fecal-
microbiota-transplantation (FMT), represent novel therapies to
prevent MS flares and improve disease course (20, 21). Thus,
we used an “n-of-1, longitudinal” design to assess whether
FMT interventions can alter the MS microbiome, decrease
inflammatory biomarkers, and improve MS symptoms in a
subject with RRMS and severe gait problem.
METHODS AND MATERIALS
Study Subject
A 48 year-old Caucasian male with active RRMS for 2
years, and complaints of difficulty in walking and bloating,
agreed to provide biological samples and undergo repeated
evaluation for 12-months before/after FMTs that he personally
decided to undergo. Subject signed the Rush University
Medical Center (RUMC) Institutional Review Board approved
informed consent form (ORA# 18082009), and study was
registered (ClinicalTrials.gov Identifier: NCT03975413). Subject
underwent an FMT administered at Taymount Clinic-Bahamas
Medical Center for treatment of MS disease, based on
subject’s own decision and not under medical direction
by RUMC doctors. Additionally, the household spouse of
the subject provided written informed consent to join the
study. The spouse provided medical information and donated
one stool sample to be used as an observational standard
of control, for the fecal experiments. Demographic/clinical
information (Supplementary Table 1).
Study Design
This single-subject study is based on repeated observations
within an individual over 12-months. Subject’s stool and serum
were collected at the following time points: before FMT (baseline:
0 week) followed by 3, 13, 26, 39, and 52 weeks. Two FMT
interventions occurred during the year-long study. First FMT
occurred between 0 and 3 weeks (Taymount Clinic); Second
FMT occurred between 26 and 39 weeks (at-home booster)
(Supplementary Figure 1). Sample collections are detailed in
Supplementary Material.
Study Procedures
The subject provided the following detailed Taymount Center
protocol to RUMC to review. The Taymount FMT protocols
and use of frozen implants, provided by the main Taymount
Center in the United Kingdom, were implemented. Prior to
the procedure, the subject provided the following test results to
the Taymount Clinic in Nassau Bahamas: blood tests (SMAC-
25, CBC, ESR, CRP, HIV, and acute viral hepatitis profiles);
stool test (Clostridium Difficile, culture and sensitivity, and ova
and parasite). These tests were normal/negative. Before the first
FMT, standard bowel prep (MiraLAX powder) was conducted
following Taymount Clinic protocol. Themorning before the first
FMT, no food or drink were consumed by the subject to keep
the colon empty. All Taymount Clinic fecal preparations were
from carefully pre-screened healthy stool donors chosen to be
transplanted into the colon of the subject. Each FMT implant was
from different donors and was numbered to ensure the subject
would get a different donor for each day. This was done to
provide a broader variety of microbiome over the multiple days
of FMT implants.
The FMT implants were frozen liquid form (each vial ∼2
total ounces of fluid with 84.5% water, 15% glycerol, and 0.5%
sodium chloride), with very little if any solids. Each FMT implant
was slowly thawed in its sealed vial in a water bath. When
thawed, the FMT implant was combined with three vials of
sodium chloride (Ph.Eur 0.9% saline Pod) in a 100ml catheter
tip syringe and the other 50ml catheter tip syringe was filled
with two vials of sodium chloride with a half pack of BiMuno
probiotic (5 g sachet). The anus and the catheter were both coated
with Vitamin A&B ointment for lubrication. With the subject
lying sideways, the 18fg closed tip rectal catheter was inserted
slowly and entirely up the colon. The FMT implant syringe was
injected first, followed by the probiotic syringe injected second,
to ensure the FMT went as far up the colon as possible. The rectal
catheter was then removed with very little spillage. Immediately
following this procedure, with the subject now lying face up, the
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stomach was rubbed up and to the left from the pelvis to the
belly button for ∼1min. Then, the subject would lie on their
right side for 10min; then their left side for 10min; and then on
their back with legs lifted for 10min. Finally, the subject would be
remained seated upright for another 30min. This completed the
FMT implant procedure for that day. Furthermore, the subject
was encouraged to refrain from making a bowel movement for
as long as possible, but at least 2 h. The subject was able to
achieve this.
In total, the subject underwent five consecutive days of FMT
implants; followed by 2 days off; then another five consecutive
days of FMT implants; and then left the Taymount Clinic
in Nassau Bahamas to return home. The subject was later
shipped multiple frozen stool boosters (stool received from
United Kingdom Certified Stool Bank) to perform the FMT
at home (similar procedural process as described above at the
Taymount Clinic), excepted the subject performed boosters for
5 days vs. 10 days, as in the original Taymount Clinic Nassau
Bahama’s session. The subject was informed by the Taymount
Clinic to perform the at-home frozen stool FMT boosters when
their overall health began to regress due to their MS symptoms,
and not based on a scheduled time frame. The subject was able to
achieve this.
Stool Microbiota Interrogation
Stool microbiota was assessed by non-targeted shotgun
metagenome sequencing and taxonomic and functional
gene profiling. Total DNA was extracted from fecal samples
utilizing the FastDNA bead-beating Spin Kit for Soil (MP
Biomedicals, Solon, OH, USA), and verified with fluorometric
quantitation (Qubit, Life Technologies, Grand Island, NY).
Library preparation was performed using the Celero DNA-Seq
library preparation protocol (Nugen, Redwood City, CA)
according to the manufacturer’s instructions. Library was
screened initially using an Illumina MiniSeq mid-output flow
cell, and re-pooled and sequenced on an Illumina HiSeq4000
instrument. Library preparation was performed at the University
of Illinois at Chicago Sequencing Core (UICSQC), and
HiSeq4000 sequencing was performed by Novogene Corp
(Chula Vista, CA).
Targeted SCFA metabolomics analysis of fecal samples
was conducted by gas chromatography. Fecal targeted SCFA
metabolite concentrations measured were acetate (mM/kg),
propionate (mM/kg), butyrate (mM/kg), total SCFA (mM/kg),
and total Butyrate-to-total SCFA ratio (mM/kg). Further




Serum Brain-Derived-Neurotrophic-Factor (BDNF) was
assessed for neuronal brain development and synaptic
plasticity (22), because BDNF has reported to be decreased
in MS and correlated with severity of CNS injury (23).
Interleukin-6 cytokine (IL-6), interleukin-8 chemokine
(IL-8), interleukin-17 (IL-17), and tumor-necrosis-factor-
alpha (TNF-α) were measured as inflammatory biomarkers
(24). These cytokines have been shown to be elevated in
MS and correlate with MS symptoms and CNS lesions
(24, 25). Enzyme-Linked-Immunosorbent-Assays used for
measurements and methodological details are provided in the
Supplementary Material.
Symptom Assessment
At the time of diagnosis, the subject could barely walk and
had significant tingling sensations in extremities, 2-years prior
to the FMT study. One-year prior to the FMT study, the
subject was walking with gait issues requiring to use cane, after
many rounds of physical therapy. Overall, the subject’s primary
MS symptom was abnormal gait. Subjective (questionnaire)
and objective (gait metrics) methods were assessed for the
impact of FMT on walking/gait status. The walking tasks
included: (1) walking normally (“gait”); (2) walking while
looking to the right or left (each gaze sustained throughout
6m; “side gaze gait”); and (3) walking while alternating gaze
right and left in a pedestrian manner (“alternating gaze gait”).
Additional gait metrics included: stride time, stride distance,
cadence, step width, average pelvis forward velocity, and pelvis
smoothness. Full methodological details are provided in the
Supplementary Material.
Clinical and Dietary Questionnaires
To assess the impact of FMT on clinical symptoms, the subject
completed the following validated questionnaires at all study
visits: 12-item MS walking scale (MSWS-12) (26), and PROMIS
gastrointestinal symptom scale (27). To determine whether the
changes in microbiota community were affected by dietary habit,
the subject completed these questionnaires: Automated Self-
Administered 24-h (ASA24 R©) recall (28), and 24-h recall Food
Timing Screener (FTS) and Food Timing Questionnaire (FTQ)
(29). MRI of the brain and spine for lesions were examined week
0 (baseline) and week 39 (after FMT1 and FMT2) collection time
points. Methodological questionnaire and MRI summary details
are provided in Supplemental Material.
Statistical Analysis
Significant differences for microbiome and pathway analysis
were summarized over time points using the linear model
R/Bioconductor software package limma (30), and adjusted
with the stringent Bonferroni post-hoc test. Targeted SCFA
metabolomics, serum biomarkers, and gait metrics significant
changes over time were assessed by parametric repeated
measures One-way ANOVA or non-parametric Friedman’s
test, based on Shapiro Wilk normality test of residuals
and Levene homogeneity of variance, which provided a P-
value for each test. Post-hoc test of Bonferroni provided
an adjusted P-value, along with each collection visit’s mean
average comparison. Additionally, Pearson correlations (log10
transformed) associations and linear regression predictions were
examined over time for all outcome experimental (e.g., gait,
Supplementary Figure 2) and clinical variables. The R, R2 and
P-values are reported. Graphs were created using GraphPad
Prism (v8.2.1).
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TABLE 1 | Change in microbial diversity across time in an RRMS FMT subject*.
Diversity metric (Taxon) Average across time
points
LFC B Stats P-value Bonferroni P-value F F
P-value
Shannon (Bacteria) 2.1433 0.0612 2.9939 0.0072 0.0287 8.9636 0.0028
Shannon (Archaea) 1.1283 0.0289 1.4144 0.1726 0.6905 2.0005 0.1572
Shannon (Fungi) 2.4650 0.0703 3.4409 0.0026 0.0103 11.8395 0.0006
Shannon (Virus) 1.4283 0.0411 2.0132 0.0577 0.2310 4.0532 0.0441
Simpson (Bacteria) −0.0917 −0.0026 −2.5554 0.0461 0.1843 6.5300 0.0461
Simpson (Archaea) −0.9350 −0.0299 −3.4112 0.0160 0.0641 11.6360 0.0160
Simpson (Fungi) −0.0117 −0.0003 −1.1778 0.2867 1.0000 1.3871 0.2867
Simpson (Virus) −0.5783 −0.0177 −3.1606 0.0216 0.0864 9.9895 0.0216
Richness (Bacteria) 12.1743 0.3461 3.3583 0.0031 0.0125 11.2784 0.0008
Richness (Archaea) 7.8332 0.2221 2.1552 0.0435 0.1740 4.6451 0.0311
Richness (Fungi) 8.9563 0.2541 2.4658 0.0228 0.0913 6.0804 0.0137
Richness (Virus) 8.8958 0.2554 2.4777 0.0223 0.0891 6.1388 0.0132
Evenness (Bacteria) −0.9317 −0.0261 −2.7450 0.0313 0.1252 7.5352 0.0313
Evenness (Archaea) −1.3083 −0.0402 −3.3618 0.0137 0.0549 11.3020 0.0137
Evenness (Fungi) −0.1717 −0.0046 −1.4305 0.1994 0.7977 2.0463 0.1994
Evenness (Virus) −1.1983 −0.0340 −2.8548 0.0269 0.1077 8.1500 0.0269
*Alpha diversity calculated at the taxonomic level of species. LFC, log fold change. Linear model R/Bioconductor software package limma performed. Log2 fold change calculated for
each time point. Weeks 0, 3, 13, 26, 39, 52 were examined across six time points. Bold value indicates adjusted P-values were significantly different at Bonferroni (P < 0.05); different
at P < 0.05.
RESULTS
Characterizations of Fecal Microbiome
Fecal microbiome was assessed for longitudinal shifts in
microbial diversity, community structure for different high-
level taxonomic groups (Bacteria, Archaea, Virus, Fungi),
and functional gene content. Alpha diversity metrics,
including Shannon index for Bacteria and Fungi, and Species
Richness for Bacteria, significantly increased across time of
study (Table 1). Microbial parameters, including ratios of
Firmicutes-to-Bacteroidetes (F/B) (Bonferroni: P = 0.0488)
and Prevotellaceae-to-Bacteroidaceae (P/B) (Bonferroni: P =
0.0143), significantly increased across time of study (Figure 1A).
The relative abundance of only a single bacterial species,
Faecalibacterium prausnitzii (butyrate-producing organism),
significantly increased across time of study (Bonferroni: P =
0.0098) (Figure 1B). Faecalibacterium prausnitzii spiked higher
before the second FMT and remained elevated, compared
to baseline. The relative abundances of two other putative
butyrate-producing species Collinsella aerofaciens (Bonferroni:
P = 0.0601) and Eubacterium rectale (Bonferroni: P = 0.0608)
increased across time of study, but corrected P-values were not
significant at P= 0.05 level.
Non-targeted analysis revealed that the abundances of five
genomic pathways, including Metabolic pathways (ko01100:
Bonferroni: P = 0.0020), Microbial metabolism in diverse
environments (ko01120: Bonferroni: P = 0.0098), Biosynthesis
of secondary metabolites (ko01110: Bonferroni: P = 0.0105),
Biosynthesis of antibiotics (ko01130: Bonferroni: P = 0.0209),
and Carbon metabolism (ko01200: Bonferroni: P = 0.0301),
were enhanced after each FMT, and significantly increased across
time of study (Figure 1C). Additionally, we hypothesized that
FMT would increase pathways involved in SCFA-production.
We observed SCFA genomic pathways were higher after
each FMT, and increased across time of study (P-value: P
< 0.0055) (Figure 1D). Complete microbiome and pathway
analysis, including spouse observational comparison, depicted in
Supplementary Figures 3–8, Supplementary Tables 2–8.
Fecal Short-Chain Fatty Acids
Metabolomics
Three principal colonic SCFAs (acetate, propionate, and
butyrate) were examined across time. Subject’s fecal SCFAs
were within or above the normal SCFA concentration ranges
(colon millimolar ratio of 60:20:20) (31). Following two FMTs,
Propionate, Butyrate, Total SCFA, and Total Butyrate-to-Total
SCFA ratio concentrations significantly increased at weeks 13 and
39. Comprehensive SCFAmetabolomics results, including spouse
observational comparison, depicted in Supplementary Figure 9,
Supplementary Table 9.
Longitudinal Assessment of Serum BDNF
and Inflammatory Biomarkers
Baseline serum BDNF (mean = 2.39 ng/ml) was below normal
range of BDNF (10–25 ng/ml). Serum BDNF was significantly
higher (Bonferroni: P ≤ 0.0002) at all time points after
FMTs, especially Week 65 (mean = 32.12 ng/ml), compared
to baseline (Figure 2A, Supplementary Table 10). After FMTs,
serum BDNF significantly increased (Bonferroni: P < 0.0001) at
weeks 3 and 39, compared to baseline and week 26.
Additionally, BDNF levels were significantly positively
correlated with the abundance of microbial SCFA-
pathway gene content (R2 < 0.90, P < 0.008) (Figure 2B,
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FIGURE 1 | Bacteria ratios, species, and genomic pathways significant movements across time of study. Differential shifts in percent relative abundance across time
for (A) bacterial ratios of Firmicutes-to-Bacteroidetes (F/B) (Bonferroni: P = 0.0488) and Prevotellaceae-to-Bacteroidaceae (P/B) (Bonferroni: P = 0.0143) and (B)
butyrate-producing species, like Faecalibacterium prausnitzii (Bonferroni: P = 0.0098). Significant differential shifts in abundance across time for (C) non-targeted
functional gene pathways (Bonferroni: P < 0.05); and (D) targeted SCFA functional gene pathways (P-value: P < 0.0055). Results were summarized over six collection
time points using the linear model R/Bioconductor software package limma, and adjusted with the stringent Bonferroni post-hoc test. Directional mean trend dotted
line shown across collection time points and FMT weeks.
Supplementary Table 21). As the neuronal blood
serum marker BDNF increased across time, our model
predicted beneficial SCFA functional genomic pathways
(i.e., pyruvate metabolism, propanoate metabolism,
fatty acid biosynthesis, fatty acid metabolism, and
butanoate metabolism) positively increased across time
of study.
Overall, serum levels of inflammatory cytokines remained
inhibited throughout the study: IL-6 (<5 pg/ml), IL-8
(<16 pg/ml), and TNF-α (<1.60 pg/ml) (Figures 2C–E,
Supplementary Table 10). While remaining within normal
range, IL-6, IL-8, and TNF-α did significantly increased following
the first FMT. After the second FMT, IL-6, and TNF-α did not
change, while IL-8 significantly decreased within normal range.
Post-hoc results between baseline and end-of-study indicated
that IL-6 levels did not change (Bonferroni: P > 0.9999); IL-8
decreased (Bonferroni: P = 0.0012); and TNF-α increased, but
remained within normal range (Bonferroni: P < 0.0001). IL-17
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FIGURE 2 | Measurement of serum biomarker changes over time of study. (A) Brain-derived neurotrophic factor (BDNF) (ng/ml) measurements significantly increased
between baseline and end of study (Bonferroni: P < 0.0001). (B) Positive linear regression relationships between BDNF and SCFA functional gene pathways across
time (R2 > 0.90, P < 0.008). (C) Interleukin-6 (IL-6) (pg/ml) did not significantly change between baseline and end of study (Bonferroni: P > 0.9999); (D) Interleukin-8
(IL-8) (pg/ml) significantly decreased between baseline and end of study (Bonferroni: P < 0.0012); and (E) Tumor necrosis factor alpha (TNF-α) (pg/ml) significantly
increased between baseline and end of study, but remained with normal range (Bonferroni: P < 0.0001). Results were summarized over seven collection time points
using repeated measures one-way ANOVA, and adjusted with the stringent Bonferroni post-hoc test. Biomarker’s classified “normal ranges” derived from ELISA
standard protocols. Directional mean trend dotted line shown across collection time points and FMT weeks. Post-hoc test adjusted P-values: ns, no significance,
* < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001.
(<0.190 pg/ml) was undetected in all seven collection time points
(data not shown). Interestingly at 26 week, BDNF decreased and
IL-8 increased (mean = 30.77 pg/ml—only time point above
normal range). This data could suggest that the subject’s overall
health was regressing which could explain why the second FMT
was administered.
Longitudinal Assessment of Gait Metrics
During the gait condition, the subject’s normal gait metrics
were primarily enhanced after each FMT, and significantly
improved over time indicating improved walking and
balance (Figures 3A–F, Supplementary Table 11). Stride
time significantly decreased over time (Bonferroni: P < 0.0001)
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indicating subject’s walking speed improved. Stride distance
significantly increased over time (Bonferroni: P < 0.0001)
suggesting subject’s walking steps increased in distance. Step
width did not change significantly from baseline to Week 52
(Bonferroni: P > 0.9999). Cadence significantly increased over
time (Bonferroni: P < 0.0001) indicating subject’s number
of steps/minute increased. Average pelvis forward velocity
significantly increased over time (Bonferroni: P < 0.0001),
approximating the increased speed of the body center of
mass. Pelvis smoothness significantly increased over time
(Bonferroni: P < 0.0001), suggesting the subject’s body walking
motion was more fluid. Side gaze gait, alternating gaze gait,
and within lab visit results in Supplementary Figures 10–12,
Supplementary Tables 12–14.
Additionally, as subject’s stride time decreased (i.e., walking
speed improved) across time, our model again predicted
beneficial SCFA functional genomic pathways (i.e., propanoate
metabolism, starch and sucrose metabolism, vitamin B6
metabolism, fatty acid metabolism, and PPAR signaling
pathway) significantly increased (R2 < 0.90, P < 0.05) across
time; as well as, inflammatory blood marker IL-6 decreased
across time (Supplementary Table 22).
12-Item MS Walking Scale Assessment
Twelve MS walking scale scores trended toward significant
improvement in the subject across time. Four of the 12MS
walking scale scores were significantly associated to the predictor
of time (weeks) (Supplementary Table 15). The subject’s ability
to climb up/or down stairs, walking balance, walking distance,
and walking smoothness significantly improved across time.
As the subject’s MS walking questionnaire scale scores
decreased across time (i.e., improved walking scores), our model
further supported predicted anti-inflammatory and immune
system beneficial gut functional genomic pathways (i.e., vitamin
B6 metabolism, flavone and flavonal biosynthesis, and PPAR
signaling pathway) significantly increased (R2 < 0.90, P < 0.05)
across time (Supplementary Table 23).
PROMIS-GI Characteristics
Four GI symptoms scales were measures across time in the
subject (Supplementary Table 16). At each collection time point,
the PROMIS GI t-score for the RRMS subject was interpreted as
“within normal limits” or “mild.” The RRMS subject’s PROMIS
GI t-score never was inferred to be “moderate” or “severe.”
The mean ± standard deviation (SD) across all six time points
collections for each PROMIS GI variable: Belly pain (56.20± 8.20
=mild); bowel incontinence (42± 7.70= within normal limits);
constipation (53.98 ± 1.88 = within normal limits); and gas &
bloating (56.33± 1.58=mild).
Baseline and Longitudinal Assessment of
Dietary Outcomes
Subject had been on gluten- and dairy-free high plant-
based diet starting prior to FMTs, and maintained this diet
throughout the study. Indeed, subject’s fecal SCFA metabolite
concentrations measured high at baseline. This is primarily
due to predominantly plant-based diet that subject begun 2-
years prior to the study. Subject’s baseline records showed
consumption of 12.5 servings of vegetables, 4.26 servings of
fruit, 3.32 servings of legumes, and 3 servings of nuts/seeds
per day. The subject’s baseline (week 0) nutrient values and the
total number of servings are depicted (Supplementary Table 17,
Supplementary Figure 13).
Sixteen ASA24 R© nutrient variables were examined across time
in the subject. Overall, the majority of ASA24 R© nutrient variables
remained stable across time, with only two variables significantly
changing (Supplementary Figure 14, Supplementary Table 18).
The subject total fruit intake significantly decreased (R2 = 0.81,
P = 0.014) across time, as the subject stopped consuming fruits
at 39 and 52 weeks (Supplementary Figure 14H). The decrease
in fruit intake is mysterious, as opposed to collection time point
0–26 weeks. It could be a result of the collection time point
date where the subject by chance skipped or intentionally did
not eat fruit. Oppositely, the subject consumed significantly
more (R2 = 0.76, P = 0.024) whole grains at 39 and 52 weeks,
whereas there was zero consumption between 0 and 26 weeks
(Supplementary Figure 14L). The dietary food logs indicated
that the whole grains consumed were both gluten free granola
bars and bread at 39 and 52 weeks. Additionally, the subject’s
total number of servings and food group changes over time are
shown (Supplementary Figures 15, 16). Finally, the ASA24 R©
nutrient variables were normalized to energy intake (1,000 kcal),
as is a common practice in nutrition literature with results
shown (Supplementary Table 19, Supplementary Figure 17).
Finally, the subject’s ASA24 R© dietary variables were compared
to experimental variables and significant relationships and
predictor outcomes (Supplementary Table 24).
Food Timing Screener/Food Timing
Questionnaire Characteristic Outcomes
The FTS/FTQ data suggests that the FMTs modified the meal
times, bedtime/wakeup, and hours slept of the subject, allowing
for additional rest on the weekend (social jet lag). The subject
indicated delayed wake-up times on the free days—Saturday
and Sunday, allowing for additional hours (1.5 h) of extra sleep
on the weekends. By waking up later on Saturday and Sunday,
the RRMS’s breakfast and lunch meal times where shifted later
into those 2 days. Overall, the impact of extra sleep from the
FMTs on free days, could suggest beneficial health effects on
the body recovering from work days (Monday thru Friday)
(Supplementary Table 20).
Safety and Tolerability
No adverse effects were noted by the subject during the clinical
study from the FMTs. It should be noted that the most common
risks of FMT are transient cramping (1–3 days), bloating
gaseousness, altered bowel habits (constipation more than
diarrhea), and low-grade fever for no more than 12–24 h. Other
risks from donor stool could include transmission of infectious
organisms; allergic reaction to antigens; abdominal pain;
and gut-related diseases, such as obesity/metabolic syndrome,
autoimmune diseases, allergic/atopic disorders, and neurological
disorders (32).
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FIGURE 3 | Measurement of normal gait metrics changes over time of study. Five of the six gait metrics significantly improved between baseline and end of study: (A)
stride time (Bonferroni: P < 0.0001); (B) stride distance (Bonferroni: P < 0.0001); (C) step width (Bonferroni: P > 0.9999); (D) cadence (Bonferroni: P < 0.0001); (E)
average forward velocity (Bonferroni: P < 0.0001); and (F) pelvis smoothness (Bonferroni: P < 0.0001). Results were summarized over four collection time points
using parametric repeated measures 1-way ANOVA or non-parametric Friedman’s test, and adjusted with the stringent Bonferroni or Dunn’s multiple group
comparison post-hoc tests. Directional mean trend dotted line shown across collection time points and FMT weeks. Post-hoc test’s adjusted P-values: ns, no
significance, * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001.
DISCUSSION
This is the first study to examine effects of FMT interventions on
a RRMS subject’s fecal microbiome using shotgunmetagenomics,
targeted metabolomics, and an array of clinical and physiological
outcomes in a year-long study. Additionally, this study provides
robust microbiome sequence data, including taxonomic and
functional gene content, through the use of shotgunmetagenome
sequencing instead of traditional 16S ribosomal RNA gene
amplicon sequencing (12).
We found FMT interventions were associated with improved
microbiome, specifically an increase in relative abundance of
“putative” anti-inflammatory butyrate-producing bacteria in
the subject’s stool, particularly Faecalibacterium prausnitzii.
During the study, FMTs were associated with significant
increased serum BDNF levels, subjective/objective evidence
of improved gait/walking matrices (primary patient’s MS
complaint), and maintained normal GI symptoms, with no
episode of RRMS symptom relapses/flare-ups over 12-months
follow-up. During follow-up clinic visits in June and July of
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2020, the subject reported no clinically significant relapses,
and was able to walk with no help and no reported
falls. Substantial increases in BDNF levels were observed
at time points immediately after FMT relative to those
before FMT.
In examining the subject’s fecal microbiome, bacterial
diversity increased with a limited number of microbial
parameters and taxa features significantly affected during the
study. Prior studies have linked an increased diversity to a
healthier microbiome (33). Similarly, higher F/B ratios have
been linked to increased SCFA-producing bacteria promoting gut
health (34), and an elevated P/B ratio has been reported with
consumption of high-fiber foods promoting gut health (35). The
increase in bacterial diversity and parameters is partly due to
increased shifts in the relative abundances of butyrate-producing
bacterial species Faecalibacterium prausnitzii, Eubacterium
rectale, and Collinsella aerofaciens. Furthermore, Butyrate
and Total Butyrate-to-SCFA ratio concentrations significantly
increased after FMTs. Butyrate-producing bacteria help regulate
the immune system and intestinal epithelial barrier (17, 18,
36). Stimulating butyrate-production by microbiome could
improve disease course, through correction of low levels
of SCFA-producers in dysbiotic microbiomes, like MS (12,
37). It is noteworthy that at each collection time point,
the subject’s fecal microbiota composition was not similar
to the household spouse control and stool SCFA levels
were higher than the spouse. The lack of similarity between
the subject and spouse fecal microbiota composition and
SCFA levels suggests the changes found in the subject are
primarily due to FMT, and are not simply the impact of
environmental factors.
Our findings that FMT had a positive impact on MS clinical
features are supported by prior reports (two patient case study)
(38, 39). Like MS, FMT has been successfully used in other
neurological disorders, supporting the notion that intestinal
microbiota plays a central role in pathogenesis of chronic
inflamamtory neurological diseases (21, 40, 41). Furthermore,
there are an increasing number of ongoing human clinical trials
evaluating FMT in RRMS that could shed more light on this
potential therapy in MS (20).
Our study had several novel features: (1) longitutinal study
that showed a sustained and durable impact of FMT on fecal
microbiota community and clinical features ofMS; (2) state of the
art shotgun metagenomics to interrogate microbiome indicating
FMT positively impacted both microbiota composition and
function with increased levels of SCFA; (3) we found significant
and sustained increase in serum BDNF levels, after FMTs. Serum
BDNF has been shown to be decreased in MS patients (23),
like our subject. BDNF is important for neuronal development
and health acting as a “fertilizer” for brain cells, keeping
them healthy, functioning and growing (22). One possible
mechanism for increased BDNF is increased abundance of
butyrate-producers after FMT, because BDNF-production is
inhibited by immune systemic inflammatory state (42), and
butyrate has anti-inflammatory activities (18). Furthermore,
we found positive correlations between serum BDNF levels
and microbiome SCFA-genomic pathways increasing over time
of study. Finally, (4) the objective measures of gait showed
that the subject’s walking and balance metrics were enhanced
after FMTs, and significantly improved over the course of the
study. During the gait condition, five of the six gait metrics
improved at 52 weeks compared to baseline, and these increased
gait metrics corresponded to improved clinical patterns and
subject’s self-reported MS walking scale scores. These gait metric
results alleviated one of the problematic MS symptoms of
walking difficulty.
These results should be taken in context of the predominantly
plant-based diet of the study subject, as previous reports
found western, high-fat, low-fiber diet promoted dysbiosis and
neuroinflammation inMS (43), while plant-based high-fiber diets
decreased MS risks (44). However, prior to the study, while on
the high-fiber diet, the subject’s symptoms remained troublesome
and led to the decision to test FMT. Nonetheless, high-fiber diet
prior to and during the study could contribute to the subject’s
robust response to FMT and increased relative abundance of
SCFA-producers (45).
This proof-of-concept study suggests that FMT might be
an emerging treatment in RRMS. This study provides evidence
of importance of intestinal microbiota in pathogenesis of
MS and scientific rationale to help design future randomized
controlled trials to determine whether FMT can modify
the intestinal microbiome to alleviate MS pathology and
symptoms. Randomized, placebo-controlled trials with
appropriate sample size will be needed to determine the
role of FMT for short- and long-term therapy for RRMS.
The major limitation of this study is that it’s a single-case,
open-labeled design were we had no input or control over
the FMT procedure administered by the Taymount Clinic.
However, longitudinal monitoring of the subject is essential
for providing insight into a potential mechanistic model of the
microbiome-gut-brain-axis regulation of neuroinflammation
in RRMS.
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